Evidence map›Paper›PMID 39279778›Full record

ArticleNeuro-oncology practice2024

Assessing sleep in primary brain tumor patients using smart wearables and patient-reported data: Feasibility and interim analysis of an observational study.

Maeve M Pascoe, Alex R Wollet, Julianie De La Cruz Minyety, Elizabeth Vera, Hope Miller, Orieta Celiku, Heather Leeper, Kelly Fernandez, Jennifer Reyes, Demarrius Young and 19 more

Abstract read
In one paragraph

Article in Neuro-oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Maeve M PascoeNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID https://orcid.org/0000-0002-3631-2677
Alex R WolletNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Julianie De La Cruz MinyetyNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Elizabeth VeraNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Hope MillerNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Orieta CelikuNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID https://orcid.org/0000-0002-0500-1032
Heather LeeperNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kelly FernandezFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Jennifer ReyesNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Demarrius YoungNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Alvina Acquaye-MalloryNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kendra AdegbesanNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Lisa BorisFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Eric BurtonNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Claudia P ChambersFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Anna ChoiNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ewa GrajkowskaNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Tricia KunstFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Jason LevineCenter for Cancer Research Office of Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Marissa PanzerFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Marta Penas-PradoNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Valentina PillaiFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Lily PolskinFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Jing WuNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID https://orcid.org/0000-0002-1686-9646
Mark R GilbertNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID https://orcid.org/0000-0003-2556-9722
Tito MendozaNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Amanda L KingNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Dorela Shuboni-MulliganFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland.
Terri S ArmstrongNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID https://orcid.org/0000-0002-2414-0492

Funding

Natural History and Specimen Banking for Patients with CNS TumorsZIABC011768 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ARMSTRONG, TERRI S. · 2017 to 2024
$6.7M
Intramural NIH HHS ZIA BC011768
6 · The paper itself

Abstract

Background: Sleep-wake disturbances are common and disabling in primary brain tumor (PBT) patients but studies exploring longitudinal data are limited. This study investigates the feasibility and relationship between longitudinal patient-reported outcomes (PROs) and physiologic data collected via smart wearables. Methods: Fifty-four PBT patients ≥ 18 years wore Fitbit smart-wearable devices for 4 weeks, which captured physiologic sleep measures (eg, total sleep time, wake after sleep onset [WASO]). They completed PROs (sleep hygiene index, PROMIS sleep-related impairment [SRI] and Sleep Disturbance [SD], Morningness-Eveningness Questionnaire [MEQ]) at baseline and 4 weeks. Smart wearable use feasibility (enrollment/attrition, data missingness), clinical characteristics, test consistency, PROs severity, and relationships between PROs and physiologic sleep measures were assessed. Results: The majority (72%) wore their Fitbit for the entire study duration with 89% missing < 3 days, no participant withdrawals, and 100% PRO completion. PROMIS SRI/SD and MEQ were all consistent/reliable (Cronbach's alpha 0.74-0.92). Chronotype breakdown showed 39% morning, 56% intermediate, and only 6% evening types. Moderate-severe SD and SRI were reported in 13% and 17% at baseline, and with significant improvement in SD at 4 weeks ( Conclusions: Collecting sleep data with Fitbits is feasible, PROs are consistent/reliable, > 10% of participants had SD and SRI that improved with smart wearable use, and SD was associated with WASO. The skewed chronotype distribution, risk and impact of sleep fragmentation mechanisms warrant further investigation. Trial Registration: NCT04 669 574.

Indexed as

brain tumorcircadian rhythmsneuro-oncologysleepsmart wearables

Identifiers

PMID39279778
PMCPMC11398942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.